Scholar Rock Holding Corporation Q3 2025 Earnings Recap

Scholar Rock faced a setback with its apitegromab application, receiving a complete response letter from the FDA, but remains optimistic about the drug's future approval for spinal muscular atrophy (SMA) thanks to strong clinical data and proactive measures.

Key Takeaways

• The FDA's complete response letter cited manufacturing issues, specifically regarding the third-party fill/finish facility, rather than concerns over apitegromab's safety or efficacy.
• Scholar Rock has initiated steps to secure an additional U.S.-based fill/finish facility to enhance production capacity and expedite future submissions.
• The company successfully strengthened its balance sheet in Q3 2025, positioning itself for strategic investments to support long-term growth.
• Regulatory meetings with the FDA were constructive, with plans for resubmission of the BLA anticipated in 2026.
• The Phase II OPAL study for apitegromab in another rare neuromuscular disorder is underway, alongside advancing SRK-439 into clinical trials.